Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 2Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 7Lymphoma 7Glioblastoma 7Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Multiple Myeloma 4Glioma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Gliosarcoma 3Burkitt Lymphoma 3Brain Neoplasms 3Astrocytoma 3Myelodysplastic Syndromes 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Central Nervous System Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Recurrence 1Primary Myelofibrosis 1Pediatric Brain Tumor 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Oligodendroglioma 1

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × Carmustine × Clear all
NCT00632827 2020-04-27

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

University of California, San Francisco

Phase 2 Terminated
21 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡